Biosite Incorporated Shares Drop On Blood Test Delays

CHICAGO (AP) -- Shares of medical diagnostic company Biosite Inc. dropped Thursday amid concerns a new blood test for strokes will see long delays at the U.S. Food and Drug Administration. Biosite shares were recently down 13.1 percent, or $7.24, to $47.87 on volume of nearly 1.2 million, compared with average daily volume of 246,000.

Back to news